Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 820-828

  Gnant, Michael F X ^a   Mlineritsch, Brigitte ^a   Luschin Ebengreuth, Gero ^a   Grampp, Stephan ^a   Kaessmann, Helmut ^a   Schmid, Marianne ^a   Menzel, Christian ^a   Piswanger Soelkner, Jutta Claudia ^a   Galid, Arik ^a   Mittlboeck, Martina ^a   Hausmaninger, Hubert ^a   Jakesz, Raimund ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; GOSERELIN; TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; NITRILE; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; AUSTRIA; BONE DENSITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA BLEEDING; VOMITING; BREAST TUMOR; DRUG EFFECT; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

ADULT; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; GOSERELIN; HUMANS; IMIDAZOLES; MIDDLE AGED; NITRILES; OSTEOPOROSIS, POSTMENOPAUSAL; TAMOXIFEN; TRIAZOLES;

EID: 33947539707     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.7102     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
2. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003
3. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
4. Coombes RC, Hall E, Gibson LJ, et al: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004
5. Goss PE, Ingle JN, Martino S, et al: Updated analysis of the NCIC CTG MA. 17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 23:87, 2004 (suppl, abstr 847)
6. Jakesz R, Kaufmann M, Gnant M, et al: Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 88:S7, 2004 (suppl 1, abstr 2)
7. Campos SM: Aromatase inhibitors for breast cancer in postmenopausal women. Oncologist 9:126-136, 2004
8. Emens LA, Davidson NE: Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 9:486S-494S, 2003 (suppl)
9. Kaufmann M, Jonat W, Blamey R, et al: Survival analyses from the ZEBRA study: Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711-1717, 2003
10. International Breast Cancer Study Group: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-1846, 2003
11. Jakesz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002
12. de Haes H, Olschewski M, Kaufmann M, et al: Quality of life in goserelin-treated versus cyclophosphamide +- methotrexate +- fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: The Zoladex Early Breast Cancer Research Association Trialists' Group. J Clin Oncol 21:4510-4516, 2003
13. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International Consensus Panel of the Treatment of Primary Breast Cancer - Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19:3817-3827, 2001
14. Sverrisdottir A, Fornander T, Jacobsson H, et al: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 22:3694-3699, 2004
15. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997
16. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997
17. Gasser JA, Green JR, Bhatnagar AS, et al: Intravenous administration of zoledronic acid offers long-term protection against bone loss in rats induced as a consequence of estrogen deprivation. Breast Cancer Res Treat 76:S78, 2002 (suppl 1, abstr 274)
18. Brufsky A, Harker W, Beck J, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): 12 mos BMD results of the Z-FAST trial. J Clin Oncol 23:12s, 2005 (suppl, abstr 533)
19. Smith MR, Eastham J, Gleason DM, et al: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012, 2003
20. WHO Study Group: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis: Report of WHO Study Group. Geneva, Switzerland, WHO, 1994, WHO Technical Report Series 843
21. Howell A: Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 82:S27, 2003 (suppl 1, abstr 129)
22. Wong Z-W, Ellis MJ: First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 90:20-25, 2004
23. Siris ES, Chen YT, Abbott TA, et al: Bone mineral density thresholds for pharmacologic intervention to prevent fractures. Arch Int Med 164:1108-1112, 2004
24. Hallberg I, Rosenqvist AM, Kartous L, et al: Health-related quality of life after osteoporotic fractures. Osteoporos Int 15:834-841, 2004
25. Legroux-Gerot I, Lormeau C, Boutry N, et al: Long-term follow-up of vertebral osteoporotic fractures treated by percutaneous vertebroplasty. Clin Rheumatol 23:310-317, 2004
26. Delmas PD, Li Z, Cooper C: Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses. J Bone Miner Res 19:330-337, 2004
27. Delmas PD, Seeman E: Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 34:599-604, 2004
28. Watts NB, Cooper C, Lindsay R, et al: Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7:255-261, 2004
29. Brufsky A, Harker G, Beck T, et al: Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (Let): Preliminary results of the Z-FAST trial. Breast Cancer Res Treat 88:S233, 2004 (suppl 1, abstr 6038)